Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

US Health Regulators Limit The Use Of J&J’s COVID Vaccine Over Blood Clot Risks – $JNJ $DIA

By John F. Heerdink, Jr.

Reportedly, the U.S. health regulator has issued notice to limit the use of the Johnson & Johnson (JNJ) COVID-19 vaccine for adults due to the high risk of a rare blood clotting syndrome. The Food and Drug Administration informed, that the J&J vaccine can be administered in cases where authorized or approved COVID-19 vaccines are not accessible or if an individual is less keen on using the other two shots (Moderna and Pfizer). The vaccine maker updated the U.S. COVID-19 vaccine fact sheet listing the risk of thrombosis with thrombocytopenia syndrome (TTS) which is a rare but potentially life-threatening condition.

Use of the J&J shot has been weak in high-income countries, hurt by reports of rare, potentially deadly blood clots, production issues, including an accidental mix-up of ingredients by a contract manufacturer, and concerns about efficacy. The U.S. Centers for Disease Control and Prevention had recommended that Americans choose to receive mRNA shots from Pfizer and Moderna over J&J’s vaccine due to the rare cases of blood clotting.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: UPDATE 3-U.S. limits use of J&J's COVID vaccine on blood clot risks in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us